VistaGen Therapeutics, Inc.
http://www.vistagen.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From VistaGen Therapeutics, Inc.
Asia Deal Watch: Betta Will Bring Two Agenus Oncology Candidates To Its Market Area
Also, deals involving Immunomic, Replicate, Biocon, DKSH, Genor, G1, Daiichi Sankyo, Esperion, Alteogen, Gelesis, China Medical System Holdings, Sosei and EverInsight.
Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro
Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.
VistaGen Hopes To Bounce Back With Spray-Based Depression Drug
NASDAQ-listed company’s shares were reduced to penny stock after trial failures in 2019, but nasal spray PH10 offers glimmer of hope.
VistaGen Stocks Neuropsychiatry Pipeline And Takes Aim At Depression Market
Shawn Singh, CEO of VistaGen, a growing Silicon Valley-based biotech focused on psychiatry and neurological drug development, outlines the company’s strategy for getting to market in the US and expanding its pipeline into new areas.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- ADMET
- Other Names / Subsidiaries
-
- VistaStem Therapeutics, Inc.